Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen

M. Correale, H. Arnberg, P. Blockx, E. Bombardier, M. Castelli, G. Encabo, M. Gion, R. Klapdor, M. Martin, S. Nilsson, H. Reutgen, G. Ruggeri, F. Safi, M. Stegmuller, A. Vering

Research output: Contribution to journalArticle

Abstract

Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPA(Cyk)) and with the established reference markers for these malignancies (CEA and NSE for lung, CA 15-3 for breast, CEA and CA 19-9 for colorectal tumors). Analysis of receiver operating characteristic (ROC) curves in lung, colorectal and bladder cancer showed similar sensitivities for the two assays, ranging from 50% to 80% with a specificity of 95%. In breast cancer all the markers studied showed poor sensitivity. However, TPA determination by either method could discriminate advanced stage (stages III and IV) from early stage disease (stages 0 to II). TPA showed similar discriminating ability in bladder cancer. On the basis of the results obtained in our patient series, it seems that of the cytokeratin markers studied, TPA and TPA-M are the most sensitive and offer a wide range of clinical applications.

Original languageEnglish
Pages (from-to)231-238
Number of pages8
JournalInternational Journal of Biological Markers
Volume9
Issue number4
Publication statusPublished - 1994

Fingerprint

Tissue Polypeptide Antigen
Immunoassay
Monoclonal Antibodies
Assays
Keratins
Urinary Bladder Neoplasms
Colorectal Neoplasms
Keratin-8
Breast Neoplasms
Keratin-18
Keratin-19
Lung
ROC Curve
Multicenter Studies
Tumors
Epitopes
Lung Neoplasms
Urinary Bladder
Breast

Keywords

  • clinical studies
  • monoclonal antibodies
  • TPA
  • tumor markers

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

Correale, M., Arnberg, H., Blockx, P., Bombardier, E., Castelli, M., Encabo, G., ... Vering, A. (1994). Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. International Journal of Biological Markers, 9(4), 231-238.

Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. / Correale, M.; Arnberg, H.; Blockx, P.; Bombardier, E.; Castelli, M.; Encabo, G.; Gion, M.; Klapdor, R.; Martin, M.; Nilsson, S.; Reutgen, H.; Ruggeri, G.; Safi, F.; Stegmuller, M.; Vering, A.

In: International Journal of Biological Markers, Vol. 9, No. 4, 1994, p. 231-238.

Research output: Contribution to journalArticle

Correale, M, Arnberg, H, Blockx, P, Bombardier, E, Castelli, M, Encabo, G, Gion, M, Klapdor, R, Martin, M, Nilsson, S, Reutgen, H, Ruggeri, G, Safi, F, Stegmuller, M & Vering, A 1994, 'Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen', International Journal of Biological Markers, vol. 9, no. 4, pp. 231-238.
Correale M, Arnberg H, Blockx P, Bombardier E, Castelli M, Encabo G et al. Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. International Journal of Biological Markers. 1994;9(4):231-238.
Correale, M. ; Arnberg, H. ; Blockx, P. ; Bombardier, E. ; Castelli, M. ; Encabo, G. ; Gion, M. ; Klapdor, R. ; Martin, M. ; Nilsson, S. ; Reutgen, H. ; Ruggeri, G. ; Safi, F. ; Stegmuller, M. ; Vering, A. / Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. In: International Journal of Biological Markers. 1994 ; Vol. 9, No. 4. pp. 231-238.
@article{318d08c99f8b49cfabfab1f2c379b9a0,
title = "Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen",
abstract = "Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPA(Cyk)) and with the established reference markers for these malignancies (CEA and NSE for lung, CA 15-3 for breast, CEA and CA 19-9 for colorectal tumors). Analysis of receiver operating characteristic (ROC) curves in lung, colorectal and bladder cancer showed similar sensitivities for the two assays, ranging from 50{\%} to 80{\%} with a specificity of 95{\%}. In breast cancer all the markers studied showed poor sensitivity. However, TPA determination by either method could discriminate advanced stage (stages III and IV) from early stage disease (stages 0 to II). TPA showed similar discriminating ability in bladder cancer. On the basis of the results obtained in our patient series, it seems that of the cytokeratin markers studied, TPA and TPA-M are the most sensitive and offer a wide range of clinical applications.",
keywords = "clinical studies, monoclonal antibodies, TPA, tumor markers",
author = "M. Correale and H. Arnberg and P. Blockx and E. Bombardier and M. Castelli and G. Encabo and M. Gion and R. Klapdor and M. Martin and S. Nilsson and H. Reutgen and G. Ruggeri and F. Safi and M. Stegmuller and A. Vering",
year = "1994",
language = "English",
volume = "9",
pages = "231--238",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen

AU - Correale, M.

AU - Arnberg, H.

AU - Blockx, P.

AU - Bombardier, E.

AU - Castelli, M.

AU - Encabo, G.

AU - Gion, M.

AU - Klapdor, R.

AU - Martin, M.

AU - Nilsson, S.

AU - Reutgen, H.

AU - Ruggeri, G.

AU - Safi, F.

AU - Stegmuller, M.

AU - Vering, A.

PY - 1994

Y1 - 1994

N2 - Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPA(Cyk)) and with the established reference markers for these malignancies (CEA and NSE for lung, CA 15-3 for breast, CEA and CA 19-9 for colorectal tumors). Analysis of receiver operating characteristic (ROC) curves in lung, colorectal and bladder cancer showed similar sensitivities for the two assays, ranging from 50% to 80% with a specificity of 95%. In breast cancer all the markers studied showed poor sensitivity. However, TPA determination by either method could discriminate advanced stage (stages III and IV) from early stage disease (stages 0 to II). TPA showed similar discriminating ability in bladder cancer. On the basis of the results obtained in our patient series, it seems that of the cytokeratin markers studied, TPA and TPA-M are the most sensitive and offer a wide range of clinical applications.

AB - Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPA(Cyk)) and with the established reference markers for these malignancies (CEA and NSE for lung, CA 15-3 for breast, CEA and CA 19-9 for colorectal tumors). Analysis of receiver operating characteristic (ROC) curves in lung, colorectal and bladder cancer showed similar sensitivities for the two assays, ranging from 50% to 80% with a specificity of 95%. In breast cancer all the markers studied showed poor sensitivity. However, TPA determination by either method could discriminate advanced stage (stages III and IV) from early stage disease (stages 0 to II). TPA showed similar discriminating ability in bladder cancer. On the basis of the results obtained in our patient series, it seems that of the cytokeratin markers studied, TPA and TPA-M are the most sensitive and offer a wide range of clinical applications.

KW - clinical studies

KW - monoclonal antibodies

KW - TPA

KW - tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0028076310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028076310&partnerID=8YFLogxK

M3 - Article

C2 - 7836801

AN - SCOPUS:0028076310

VL - 9

SP - 231

EP - 238

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -